4//SEC Filing
RA Capital Healthcare Fund LP 4
Accession 0001231919-25-000527
CIK 0002036042other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 8:43 PM ET
Size
54.0 KB
Accession
0001231919-25-000527
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
- Sale
Common Stock
2025-11-19$40.61/sh−2$81→ 6,899,079 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$40.20/sh−17,913$720,103→ 698,075 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$40.20/sh−13,734$552,107→ 195,657 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$42.10/sh−53$2,231→ 6,901,689 total(indirect: See footnotes) - Sale
Common Stock
2025-11-18$39.57/sh−1,770$70,039→ 2,217,969 total(indirect: See footnotes) - Sale
Common Stock
2025-11-18$39.57/sh−2,092$82,780→ 182,527 total(indirect: See footnotes) - Sale
Common Stock
2025-11-19$40.01/sh−12,126$485,161→ 2,205,843 total(indirect: See footnotes) - Sale
Common Stock
2025-11-19$40.61/sh−9$365→ 168,193 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$40.20/sh−11,626$467,365→ 2,229,082 total(indirect: See footnotes) - Sale
Common Stock
2025-11-19$40.61/sh−12$487→ 662,254 total(indirect: See footnotes) - Sale
Common Stock
2025-11-19$40.61/sh−8$325→ 2,205,835 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$41.05/sh−1,701$69,826→ 6,901,742 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$42.10/sh−331$13,935→ 184,619 total(indirect: See footnotes) - Sale
Common Stock
2025-11-18$39.57/sh−2,728$107,947→ 680,950 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$41.05/sh−13,964$573,222→ 684,111 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$41.05/sh−10,707$439,522→ 184,950 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$42.10/sh−433$18,229→ 683,678 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$42.10/sh−280$11,788→ 2,219,739 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$40.20/sh−2,182$87,716→ 6,903,443 total(indirect: See footnotes) - Sale
Common Stock
2025-11-17$41.05/sh−9,063$372,036→ 2,220,019 total(indirect: See footnotes) - Sale
Common Stock
2025-11-19$40.01/sh−2,276$91,063→ 6,899,081 total(indirect: See footnotes) - Sale
Common Stock
2025-11-19$40.01/sh−18,684$747,547→ 662,266 total(indirect: See footnotes) - Sale
Common Stock
2025-11-18$39.57/sh−332$13,137→ 6,901,357 total(indirect: See footnotes) - Sale
Common Stock
2025-11-19$40.01/sh−14,325$573,143→ 168,202 total(indirect: See footnotes)
Footnotes (10)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
- [F3]RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F4]Held directly by the Nexus Fund.
- [F5]Held directly by the Nexus Fund III.
- [F6]Held directly by the Account.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.13 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Sionna Therapeutics, Inc.
CIK 0002036042
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001315082
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 8:43 PM ET
- Size
- 54.0 KB